NANOTECH RCC Biomarkers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02923284|
Recruitment Status : Recruiting
First Posted : October 4, 2016
Last Update Posted : September 23, 2019
|Condition or disease|
|Renal Cell Carcinoma Renal Cell Cancer|
|Study Type :||Observational|
|Estimated Enrollment :||1200 participants|
|Official Title:||Nanotech Biomarkers For Renal Cancer Intervention: Clinical Validation & Utility|
|Study Start Date :||August 2016|
|Estimated Primary Completion Date :||August 31, 2020|
|Estimated Study Completion Date :||August 31, 2020|
Imaged renal mass cohort
Subjects undergoing surgery for an kidney tumor identified radiologically.
Subjects undergoing surgery for any kind of cancer other than kidney.
- Urine AQP1 [ Time Frame: 28 days ]Assay results will be compared to the pathology report for the excised renal mass and the ICD10 codes.
- PLIN2 concentration [ Time Frame: 28 days ]Assay results will be compared to the pathology report for the excised renal mass and the ICD10 codes.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02923284
|Contact: Jeremiah Morrissey, PhD||(314) firstname.lastname@example.org|
|United States, Missouri|
|Washington University St Louis School of Medicine||Recruiting|
|Saint Louis, Missouri, United States, 63110|
|Contact: Cynthia Tang, BS 314-747-1690 email@example.com|
|Principal Investigator:||Jeremiah Morrissey, PhD||Washington University School of Medicine|